As a patient organization dedicated to helping lymphoma patients get equal access to treatment options across the country, Lymphoma Canada is thrilled to be hosting an education webinar series this fall on novel targeted therapies. This series will cover three novel and relevant topics including Precision-based Medicine & Research, Bispecific Antibody Therapy and CAR T-cell therapy. Please join us to learn more about these novel treatment options & how you can access them in Canada!
Webinars in this series include:
Read below for more information.
Webinar 1: Precision-based Medicine & Research
Wednesday, November 9, 2022
4:00 – 5:00 pm EST
As the first webinar in the Novel Lymphoma Therapies series, Dr. Michael Rauh and two of his trainees will provide an overview of precision-based medicine & research. This presentation will define what personalized medicine is, and how research can help doctors choose treatment options based on an individual’s genetic and molecular profile of cancer. This talk will highlight how precision-based medicine & research can help lymphoma patients access treatment options in Canada.
Dr. Michael Rauh, Dr. Gillian Kupakuwana-Suk, Mr. Marco Buttigieg
Dr. Michael Rauh
Dr. Michael Rauh is a staff hematopathologist at the Kingston General Hospital and an Assistant Professor in the department of Pathology & Molecular Medicine at Queen’s University. He leads a research group that studies genetic and immune pathogenesis of myeloid cancer. Dr. Rauh and his students are dedicated to discovering novel biomarkers and treatment targets, supporting personalized diagnosis and care for those diagnosed with hematological malignancies.
Dr. Gillian Kupakuwana-Suk
Gillian Kupakuwana-Suk is a 4th year hematology resident at Queen’s University and recently joined Dr. Rauh’s lab with a focus on clonal hematopoiesis in Lymphoma. She attended medical school at Columbia University in New York and completed her internal medicine training at Yale and has a keen interest in understanding mutational evolution leading up to hematologic malignancies.
Mr. Marco Buttigieg
Marco is a 4th year undergraduate student in the Bachelor of Health Sciences program at Queen’s University. He is currently completing his thesis project in Dr. Rauh’s lab studying how clonal hematopoiesis can influence cancer progression and metastasis and will be continuing with his studies in the lab next year for his master’s degree. He is from Toronto, Ontario.
Webinar 2: Bispecific Antibody Therapy
Wednesday, November 16, 2022
4:00 – 5:00 pm EST
In the second educational webinar, Dr. Michael Crump from Princess Margaret Hospital will cover what bispecific antibodies are and how this novel therapy can help lymphoma patients across Canada. This talk will highlight who is eligible for bispecific antibody therapy and the clinical trials available for lymphoma patients in Canada.
Dr. Michael Crump
Michael Crump is a hematologist in the Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre, and Professor of Medicine at the University of Toronto. His clinical and research interests are primary and second line therapy of lymphoid malignancies, investigation of novel therapies and in autologous stem cell transplantation. He is currently the Co-Chair of the Hematology Disease Site Group and the Lymphoma Working Group Chair for the Canadian Cancer Trials Group (CCTG).
Webinar 3: CAR T-cell Therapy
Wednesday, November 23, 2022
4:00 – 5:00 pm EST
For the final webinar in the Novel Targeted Therapies series, Dr. Mark Bosch from Saskatchewan Cancer Agency will discuss relevant and novel research on CAR T-cell therapy. This presentation will cover where CAR T-cell therapy can be accessed in Canada and who is eligible for this treatment option. Overall, this webinar will help you and your loved ones better understand how modern science & medicine can re-program an individual’s immune system can to treat hematological cancers.
Dr. Mark Bosch
Dr. Mark Bosch is a stem cell transplant physician at the Saskatoon Cancer Centre. He completed his medical school and internal medicine at the University of Saskatchewan. He completed his sub-specialty in Hematology and Bone Marrow Transplant at the University of Calgary. Dr. Bosch is very active in administration, teaching, and clinical research in leukemia, lymphoma, CAR T and bone marrow transplantation.